2/3 of the way through the quarter so no I don't think so. Based upon the AGM presentation I think a lot of the growth (from the US) is dependent upon ongoing trials which won't complete until Q3 & as such will turn into sales in the mid to later half of H2.
Europe is in lockdown & so demand will continue to be at a lower level there in Q2 IMO.
All IMO, very difficult to predict ZNO revenue. H1 FY21 could be as low as $20m or as high as $30m, the above is just where I think it will end up.
ZNO Price at posting:
$1.39 Sentiment: Buy Disclosure: Held
